Global biotechs are increasingly leaning on CDMOs to meet rising manufacturing, regulatory, and operational complexities. CDMOs deliver specialised expertise, flexible production capacity, and proven GMP systems that support rapid progression from early development to commercial scale. By collaborating with CDMOs, biotechs can focus on discovery while ensuring their therapies are manu... https://xellera.livejournal.com/4599.html